Synergy CHC Corp. Accounts Receivable, Allowance for Credit Loss
Synergy CHC Corp. (SNYR) had Accounts Receivable, Allowance for Credit Loss of $377.58 thousand as of 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-04-01
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $377.58K.
- 2020-03-31: Accounts Receivable, Allowance for Credit Loss $113.66K.
- 2019-12-31: Accounts Receivable, Allowance for Credit Loss $283.97K; Accounts Receivable, Allowance for Credit Loss as first filed $283.97K.
- 2019-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2025-12-31 | $377.58K 10-K · filed 2026-04-01 | |
| 2020-03-31 | $113.66K 10-Q · filed 2020-06-29 | |
| 2019-12-31 | $283.97K 10-Q · filed 2020-06-29 | $283.97K 10-K · filed 2020-04-29 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $0.00 10-K · filed 2020-04-29 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 | |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | |
| 2015-12-31 | $121.29K 10-K · filed 2017-03-24 | -$121.29K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |